Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tergenpumatucel-L in Refractory or Recurrent NSCLC
NCT00073398Phase 2Completed
- Sponsor
- Lumos Pharma, Inc.
- Start
- Nov 2003
- Primary completion
- Nov 2012
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tergenpumatucel-l in non-small cell lung cancer (NSCLC), sponsored by Lumos Pharma, Inc. Primary endpoints: Safety at Day 127 and Objective Response Rate at Day 127. Started Nov 2003; status: completed.
02
Drugs
tergenpumatucel-l
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00073398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00073398.